Moreover, it is interesting to note that Ménard et al. had demonstrated that CTLA-4 blockade with tremelimumab in advanced melanoma patients restored the circulating effector and memory CD4+ and CD8+ T cell pool and TCR-dependent T-cell proliferation that became resistant to Treg-mediated suppression [30]. This evidence concerns the gene CTLA4 and melanoma.